Montelukast Actavis (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes D4, E4 and related mediators from binding. This action reduces bronchoconstriction, airway inflammation, and mucus production, leading to improved airflow and symptom relief in leukotriene‑driven respiratory diseases.

The specific dose of Montelukast Actavis is determined by the prescribing clinician based on the patient’s age, condition severity, and response to therapy. Healthcare providers set the appropriate regimen and adjust it as needed.

Safety data for Montelukast Actavis in pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk. During breastfeeding, a risk‑benefit assessment is also required, and the prescriber should decide whether to continue treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Montelukast is a leukotriene receptor antagonist, whereas inhaled corticosteroids are anti‑inflammatory agents that act directly on airway cells. Montelukast is often used as an add‑on therapy for patients whose asthma is not fully controlled by inhaled steroids, but it does not replace the anti‑inflammatory effect of corticosteroids.

Montelukast Actavis tablets should be stored at temperatures below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and avoid storing in areas with high humidity or heat.

Montelukast Actavis is taken orally, usually as a whole tablet with or without food. The exact timing (e.g., morning or evening) is decided by the prescriber based on the patient’s treatment plan.

Serious risks include mood changes such as depression or suicidal thoughts, severe allergic reactions (e.g., angioedema, anaphylaxis), and rare but serious skin reactions like Stevens‑Johnson syndrome. Patients should be monitored for any new or worsening psychiatric symptoms or allergic signs.

Montelukast Actavis should be avoided in patients with known hypersensitivity to montelukast or any of the tablet’s excipients. Caution is also advised for individuals with a history of severe psychiatric disorders, liver disease, or those taking medications that may cause major drug interactions.